KPWS
ALLO icon

Kestra Private Wealth Services’s Allogene Therapeutics ALLO Stock Holding History

Kestra Private Wealth Services’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.5K Buy
12,729
+1,820
+17% +$4K ﹤0.01% 1784
2026
Q1 		$26.6K Buy
+10,909
New +$21.9K ﹤0.01% 1732

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Kestra Private Wealth Services's ALLO Position: Q2 2026 in Review

Kestra Private Wealth Services increased its Allogene Therapeutics (ALLO) stake by 17% in Q2 2026, buying an estimated $4K and bringing the position to 12,729 shares worth $26.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1784.

Kestra Private Wealth Services first reported a position in ALLO in Q1 2026 and has held it in 2 quarters since. The position peaked at $26.6K in Q1 2026. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Kestra Private Wealth Services held 12,729 shares of Allogene Therapeutics worth $26.5K as of Q2 2026.
  • Kestra Private Wealth Services bought 1,820 Allogene Therapeutics shares in Q2 2026, an estimated $4K.
  • Allogene Therapeutics made up ﹤0.01% of Kestra Private Wealth Services's portfolio in Q2 2026, its #1784 holding.
  • Kestra Private Wealth Services first reported a position in Allogene Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Kestra Private Wealth Services's Allogene Therapeutics position peaked at $26.6K in Q1 2026.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Kestra Private Wealth Services's 13F filing for Q2 2026, filed 28 Jul 2026.